Hemorheological disturbances, metabolic parameters and blood pressure in different types of obesity

We investigated whether visit-to-visit variability in metabolic parameters is associated with lung cancer risk. We used nationally representative data from the Korean National Health Insurance System, and 8,011,209 lung-cancer-free subjects who underwent over three health examinations from 2005 to 2010 were followed until 2017. Variability of fasting blood glucose, total cholesterol, systolic blood pressure, and body weight were measured by the variability independent of the mean, assessed by quartiles. There were 44,982 lung cancer events. The hazard ratio (HR) and 95% confidence interval (CI) for lung cancer risk was 1.07 (1.04, 1.10) for fasting blood glucose in the highest quartile, 1.08 (1.05, 1.10) for systolic blood pressure, 1.04 (1.01, 1.07) for weight, and 1.11 (1.08, 1.14) for total cholesterol. When comparing ≥3 vs. 0 high-variability metabolic parameters, the HR for lung cancer was 1.18 (95% CI, 1.14, 1.22). However, while ≥3 high-variability parameters showed an increased lung cancer risk in men (HR 1.26, 95% CI 1.21, 1.31), women did not show increased risk (HR 0.99, 95% CI 0.92, 1.06). High variability in each metabolic parameter, and a higher number of high-variability parameters, were associated with increased lung cancer risk.

Download Full-text

Effects of Variability in Blood Pressure, Glucose, and Cholesterol Concentrations, and Body Mass Index on End-Stage Renal Disease in the General Population of Korea

Journal of Clinical Medicine ◽

10.3390/jcm8050755 ◽

2019 ◽

Vol 8 (5) ◽

pp. 755 ◽

Cited By ~ 5

Author(s):

Mee Kyoung Kim ◽

Kyungdo Han ◽

Hun-Sung Kim ◽

Yong-Moon Park ◽

Hyuk-Sang Kwon ◽

...

Keyword(s):

Blood Pressure ◽

Body Mass Index ◽

General Population ◽

Renal Disease ◽

End Stage Renal Disease ◽

High Variability ◽

Metabolic Parameters ◽

Metabolic Parameter ◽

Stage Renal Disease ◽

End Stage

Aim: Metabolic parameters, such as blood pressure, glucose, lipid levels, and body weight, can interact with each other, and this clustering of metabolic risk factors is related to the progression to end-stage renal disease (ESRD). The effect of variability in metabolic parameters on the risk of ESRD has not been studied previously. Methods: Using nationally representative data from the Korean National Health Insurance System, 8,199,135 participants who had undergone three or more health examinations between 2005 and 2012 were included in this analysis. Intraindividual variability in systolic blood pressure (SBP), fasting blood glucose (FBG), total cholesterol (TC), and body mass index (BMI) was assessed by examining the coefficient of variation, variability independent of the mean, and average real variability. High variability was defined as the highest quartile of variability and low variability was defined as the lower three quartiles of variability. Results: Over a median (5–95%) of 7.1 (6.5–7.5) years of follow-up after the variability assessment period, 13,600 (1.7/1000 person-years) participants developed ESRD. For each metabolic parameter, an incrementally higher risk of ESRD was observed for higher variability quartiles compared with the lowest quartile. The risk of ESRD was 46% higher in the highest quartile of SBP variability, 47% higher in the highest quartile of FBG variability, 56% higher in the highest quartile of BMI variability, and 108% higher in the highest quartile of TC variability. Compared with the group with low variability for all four parameters, the group with high variability for all four parameters had a significantly higher risk for incident ESRD (hazard ratio (HR) 4.12; 95% CI 3.72–4.57). Conclusions: Variability in each metabolic parameter was an independent predictor of the development of ESRD among the general population. There was a composite effect of the variability in additional metabolic parameters on the risk of ESRD.

Download Full-text

Treating obesity with sibutramine under practical conditions. Positive effects on the metabolic parameters and blood pressure.

Obesity and metabolism ◽

10.14341/2071-8713-4932 ◽

2005 ◽

Vol 2 (2) ◽

pp. 51-52

Author(s):

Keyword(s):

Blood Pressure ◽

Metabolic Parameters ◽

Positive Effects

Download Full-text

Effects of a Meal Replacement on Body Composition and Metabolic Parameters among Subjects with Overweight or Obesity

Journal of Obesity ◽

10.1155/2018/2837367 ◽

2018 ◽

Vol 2018 ◽

pp. 1-10 ◽

Cited By ~ 5

Author(s):

Xiaohui Guo ◽

Yifan Xu ◽

Hairong He ◽

Hao Cai ◽

Jianfen Zhang ◽

...

Keyword(s):

Blood Pressure ◽

Body Composition ◽

Total Energy ◽

Intervention Group ◽

Overweight And Obesity ◽

Metabolic Parameters ◽

Control Group ◽

Meal Replacement ◽

Significant Difference ◽

The Impact

Meal replacement plans are effective tools for weight loss and improvement of various clinical characteristics but not sustainable due to the severe energy restriction. The aim of the study was to evaluate the impact of meal replacement, specifically 388 kcal in total energy, on body composition and metabolic parameters in individuals with overweight and obesity from a Chinese population. A parallel, randomized controlled trial was performed with 174 participants (ChiCTR-OOC-17012000). The intervention group (N=86) was provided with a dinner meal replacement, and the control group (N=88) continued their routine diet as before. Body composition and blood parameters were assessed at 0, 4, 8, and 12 weeks. A post hoc analysis (least significant difference (LSD) test), repeated measurements, and pairedT-test were used to compare each variable within and between groups. Significant (p<0.001) improvements in body composition components were observed among the intervention group, including body weight (−4.3 ± 3.3%), body mass index (−4.3 ± 3.3%), waist circumference (−4.3 ± 4.4%), fat-free mass (−1.8 ± 2.9%), and body fat mass (−5.3 ± 8.8%). Body composition improvements corresponded with significant metabolic improvements of blood glucose (−4.7 ± 9.8%). Further improvements in visceral fat area (−7.7 ± 10.1%), accompanying with improvements in systolic (−3.7 ± 6.9%) and diastolic (−5.3 ± 7.7%) blood pressure, were only found in male subjects. To conclude, meal replacement intake with 388 kcal in total energy at dinner time for 12 weeks contributed to improvement in body composition and clinically significant metabolic parameters in both male and female participants with overweight/obesity. Additionally, glucose and blood pressure reduction were gender-specific highlighting the importance of gender stratification for design of nutritional intervention studies for improvement of health.

Download Full-text

ACUTE EFFECT OF DIFFERENT TYPES OF EXERCISE ON BLOOD PRESSURE OF HYPERTENSIVE OLDER WOMEN

Innovation in Aging ◽

10.1093/geroni/igx004.2345 ◽

2017 ◽

Vol 1 (suppl_1) ◽

pp. 661-661

Author(s):

G.O. Campos ◽

R.F. Bertani ◽

J.C. Moriguti ◽

E. Ferriolli ◽

N.K. Lima

Keyword(s):

Blood Pressure ◽

Older Women ◽

Acute Effect ◽

Different Types

Download Full-text

Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients

Arquivos Brasileiros de Endocrinologia & Metabologia ◽

10.1590/s0004-27302006000600007 ◽

2006 ◽

Vol 50 (6) ◽

pp. 1020-1025 ◽

Cited By ~ 8

Author(s):

Camila Guimarães ◽

Leonardo R.L. Pereira ◽

Nélson Iucif Júnior ◽

Evandro José Cesarino ◽

Carlos A.N. de Almeida ◽

...

Keyword(s):

Blood Pressure ◽

Side Effects ◽

Waist Circumference ◽

Hdl Cholesterol ◽

Metabolic Parameters ◽

Abdominal Circumference ◽

Fatty Tissue ◽

Obese Patients ◽

Adjunct Therapy

The aim of this study is to assess the effects of sibutramine (S) 15 mg/day, fluoxetine (F) 60 mg/day, and metformin (M) 1,700 mg/day, as an adjunct therapy to a 1,500 kcal/day diet, in reducing anthropometric and metabolic parameters. S (n= 8), F (n= 9), and M (n= 8) were compared to placebo (n= 10) in 35 obese patients in a 90-day trial. Side effects were also studied during the treatment. The data demonstrated that F therapy resulted in a greater average reduction in BMI (11.0%), weight (10.0%), abdominal circumference (11.0%) and %fatty-tissue (12.8). An elevation in HDL-cholesterol (25.8%) and a reduction in average triglyceride levels (28.3%) were also shown. S presented a 7.91% reduction in the abdominal circumference and a 9.65 reduction in %fatty-tissue was also found. M group presented reductions in BMI (4.03%), waist circumference (6.92%), HOMA (23.5%) and blood pressure (6.08% in systolic and 2.08% in diastolic). In general, the three drugs can be considered well tolerated. We concluded that F and S demonstrated a greater mean reduction in anthropometric and metabolic parameters when compared to M, however all of them are useful for that purpose, when the subjects’ characteristics are considered.

Download Full-text

Different types of amyloid concomitantly present in the same patients

Hematology Reports ◽

10.4081/hr.2019.7996 ◽

2019 ◽

Vol 11 (4) ◽

Author(s):

Francesca Martini ◽

Gabriele Buda ◽

Vincenzo De Tata ◽

Sara Galimberti ◽

Enrico Orciuolo ◽

...

Keyword(s):

Electron Microscopy ◽

Blood Pressure ◽

Amyloid Fibrils ◽

Stem Cell Transplant ◽

Troponin T ◽

Immunogold Electron Microscopy ◽

Al Amyloidosis ◽

Cell Transplant ◽

Plasma Cell Disorders ◽

Different Types

Different types of amyloid concomitantly present in the same patient is believed to be improbable. We reported four cases of patients with plasma cell disorders who were found to have biopsy proven concomitant different types of amyloid fibrils deposition. We characterized amyloid fibrils using immunogold electron microscopy. There is lack of experience in the treatment of these frail and elderly patients, who are on the threshold between necessity of chemotherapy for AL amyloidosis and necessity to avoid harmful treatment related toxicity. All patients with a systemic amyloid syndrome require therapy to prevent deposition of amyloid in other organs and prevent progressive organ failure. Stem cell transplant (SCT) is preferred, but only 20% of patients are eligible Requirements for safe SCT include systolic blood pressure >90 mm Hg, troponin T <0.06 ng/mL, age <70 years, and serum creatinine ≤1.7 mg/dL Nontransplant candidates can be offered melphalandexamethasone or cyclophosphamide-bortezomibdexamethasone.

Download Full-text